Privi Speciality Chemicals (PRIVISCL) Q1 25/26 earnings summary

Executive summary

• Achieved EcoVadis Platinum rating, placing in the top 1% globally for ESG performance, reflecting strong sustainability and efficient business practices.

• Announced a proposed merger/amalgamation of Privi Fine Sciences, Privi Biotechnologies, and Privi Speciality Chemicals to simplify structure and unlock growth.

• Strategic focus on innovation, resilience, and building a world-class aroma chemical company with a leading market position.

• Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with limited review reports expressing unmodified conclusions.

Financial highlights

• Standalone revenue for Q1 FY25-26 was ₹56,635.59 lakhs, up from ₹44,116.43 lakhs year-over-year; consolidated revenue was ₹55,881.24 lakhs, up from ₹46,397.56 lakhs.

• Standalone EBITDA increased by 50.4% and consolidated EBITDA by 45.3% year-over-year; EBITDA margin at 24.8%.

• Standalone PAT rose 113.3% and consolidated PAT 97.1% year-over-year; standalone net profit was ₹6,868.86 lakhs, consolidated net profit attributable to owners was ₹6,193.07 lakhs.

• Basic and diluted EPS (standalone) was ₹17.58, up from ₹8.25 year-over-year; consolidated EPS was ₹15.85, up from ₹8.05 year-over-year.

• Exports contributed about 70% of revenue.

Outlook and guidance

• Targeting INR 5,000 crore revenue and INR 1,000 crore EBITDA within 3–5 years.

• Expecting to maintain EBITDA margins above 20% and sustain 20% annual growth.

• Phase 1 of capacity expansion partly completed, contributing from Q2 FY26; full completion expected in Q4 FY26, supporting further growth in FY27.

• Strong demand outlook driven by niche fragrance trends, sustainable innovation, and expanding Asian markets.

• Financial results and outlook are available for investors on company and stock exchange websites.